Saturday 17 October 2026
Export PRGO’s income statement to Excel — free account
Perrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 3.17%, EPS grew 1,000.0%, free cash flow grew 18.4% and total debt fell 9.78%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.
16.63
0.15
+0.91%
Follow PRGO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 4 | 4 |
| (1.15%) | (39.29%) | (52.97%) | (49.65%) | ||
| (0.49%) | (15.68%) | (20.49%) | (19.60%) | ||
ROIC |
2.28% | (11.60%) | (16.68%) | (18.06%) | |
Return on Tangible Assets |
(1.96%) | (53.12%) | (70.11%) | (77.24%) | |
Average Days of Receivables |
54.93 | 52.59 | 60.89 | 62.51 | |
Free Cash Flow per Share |
2.05 | 1.11 | 0.83 | 0.86 | |
Free Cash Flow |
283.60 | 153.40 | 115.70 | 119.30 | |
Capital Expenditures |
(92.10) | (85.10) | (73.70) | (76.80) | |
| Other line items | |||||
Cash ROIC |
3.33% | 2.16% | 1.78% | 1.92% | |
Accounts Receivable Turnover |
5.99 | 6.78 | 5.91 | 5.97 | |
Accounts Payable Turnover |
5.95 | 5.69 | 5.87 | 6.22 | |
Inventory Turnover |
2.34 | 2.47 | 2.42 | 2.43 | |
Average Days of Payables |
62.04 | 62.78 | 57.70 | 52.83 | |
Days of Inventory on Hand |
162.05 | 152.03 | 148.80 | 140.46 | |
Tax Rate |
(1.28) | 0.08 | 0.05 | 0.06 | |
Research and Development Expense of Revenue |
2.37% | 2.24% | 2.23% | 2.29% | |
Selling, General and Administrative Expense of Revenue |
24.17% | 24.82% | 24.94% | 24.61% | |
Share Based Compensation of Revenue |
1.44% | 1.28% | 1.37% | 1.14% | |
Interest Coverage |
1.72 | (6.91) | (9.38) | (9.58) | |
Operating CF/Net income |
(7.27) | (0.17) | (0.10) | (0.11) | |
Depreciation/Fixed assets |
0.38 | 0.39 | 0.40 | 0.42 | |
Capex/Depreciation |
(0.27) | (0.25) | (0.21) | (0.21) | |
Revenue per Share |
30.92 | 30.71 | 30.13 | 29.80 | |
Operating CF per Share |
2.71 | 1.72 | 1.37 | 1.41 | |
Capex per Share |
(0.66) | (0.61) | (0.53) | (0.55) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates